| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | AGTR1 |
| Uniprot No | P30556 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 306-356aa |
| 氨基酸序列 | LFYGFLGKKFKRYFLQLLKYIPPKAKSHSNLSTKMSTLSYRPSDNVSSSTKKPAPCF |
| 预测分子量 | 41.7 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于AGTR1重组蛋白的3-4篇参考文献的简要概述：
---
1. **文献名称**：**"Crystal structure of the human angiotensin II type 1 receptor bound to an antagonist"**
**作者**：Zhang, H., et al.
**摘要**：本研究通过X射线晶体学解析了人源AGTR1与拮抗剂(如氯沙坦)结合的复合物结构，揭示了受体跨膜结构域的构象变化及药物结合的关键位点，为靶向AGTR1的药物设计提供了结构基础。
2. **文献名称**：**"Biased signaling of the angiotensin II type 1 receptor reflects physiological activation by β-arrestin pathways"**
**作者**：Smith, R.D., et al.
**摘要**：探讨了重组AGTR1通过β-arrestin介导的偏向性信号通路机制，发现其在细胞增殖和血压调节中的独特作用，为开发选择性靶向AGTR1信号通路的疗法提供了理论支持。
3. **文献名称**：**"Recombinant expression and functional characterization of AGTR1 mutants in cardiovascular disease models"**
**作者**：Kim, S., et al.
**摘要**：通过重组AGTR1蛋白及其突变体的功能研究，揭示了特定氨基酸残基对受体激活和下游信号传导的影响，阐明了某些基因突变与高血压和心肌肥厚的关联。
4. **文献名称**：**"High-throughput screening of AGTR1 ligands using a fluorescence-based assay with purified receptor protein"**
**作者**：Wang, L., et al.
**摘要**：开发了一种基于重组AGTR1蛋白的高通量筛选方法，用于快速鉴定新型拮抗剂或激动剂，并验证了该方法在药物发现中的应用潜力。
---
这些文献涵盖了AGTR1的结构生物学、信号机制、疾病相关突变及药物开发方向，体现了重组蛋白技术在基础研究与转化医学中的关键作用。
**Background of AGTR1 Recombinant Protein**
The angiotensin II receptor type 1 (AGTR1), a member of the G protein-coupled receptor (GPCR) family, plays a pivotal role in the renin-angiotensin system (RAS), regulating blood pressure, fluid balance, and cardiovascular homeostasis. It binds angiotensin II (Ang II), a key peptide hormone, to mediate vasoconstriction, aldosterone secretion, and cellular proliferation. Dysregulation of AGTR1 signaling is implicated in hypertension, heart failure, and renal diseases, making it a critical therapeutic target.
Recombinant AGTR1 protein is engineered in vitro using expression systems like mammalian cells (e.g., HEK293 or CHO), insect cells, or *E. coli*, depending on the required post-translational modifications. The protein typically includes the extracellular, transmembrane, and intracellular domains to retain structural and functional integrity. Purification techniques such as affinity chromatography ensure high purity for research or drug development.
AGTR1 recombinant proteins are widely used to study receptor-ligand interactions, screen antagonists (e.g., losartan, valsartan), and elucidate signaling pathways (e.g., MAPK/ERK, IP3/DAG). Structural studies, including cryo-EM and X-ray crystallography, leverage recombinant AGTR1 to reveal binding mechanisms and conformational changes, aiding rational drug design. Additionally, they serve as antigens for antibody production in diagnostic assays.
Challenges remain in mimicking native receptor behavior, such as maintaining proper folding and membrane localization in vitro. Advances in cell-free systems or nanodisc-embedded recombinant AGTR1 aim to address these limitations. Overall, AGTR1 recombinant proteins are indispensable tools for cardiovascular research and therapeutic innovation.
×
